Our pipeline

澳门第一赌城在线娱乐有一个令人兴奋和平衡的管道,由伟大的科学支撑.

Home / Our therapy areas / Our pipeline

Latest quarterly updates

澳门第一赌城在线娱乐的产品线在临床开发的不同阶段形成了强大的研究性疗法组合.


179

projects in our pipeline

15

new molecular entities in our late-stage pipeline

1

new molecular entity approved


III期/LCM项目:指II/III期的关键资产, 或者已经提交监管审批的, 可能包括现在在一个或多个主要市场推出的资产(在所有适用的主要市场推出时删除).

Filter By:

Oncology (as of 9 February 2023)

Phase I

Phase I

  • AZD0466 haematological malignancies
  • AZD1390 glioblastoma
  • AZD7789 solid tumours, haematological malignancies
  • AZD8853 solid tumours
  • AZD9574 advanced solid malignancies
  • AZD9592 solid tumours
  • IPH5201 solid tumours
  • volrustomig + lenvatinib advanced renal cell carcinoma

Phase II

Phase II

  • AZD0171 + Imfinzi + CTx 一线转移性胰腺导管腺癌
  • AZD4573 haematological malignancies
  • AZD4573 + Calquence haematological malignancies
  • AZD5305 solid tumours
  • AZD8205 solid tumours
  • camizestrant estrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • ceralasertib solid tumours
  • Imfinzi + monalizumab solid tumours
  • oleclumab+CTx or Imfinzi+oleclumab+CTx metastatic pancreatic cancer
  • rilvegostomig (AZD2936) ARTEMIDE-01 solid tumours
  • volrustomig solid tumours

Phase III

Phase III

  • camizestrant + CDK4/6i SERENA-6 1st-line HR+ HER2- ESR1m breast cancer
  • camizestrant + palbociclib SERENA-4 1st-line HR+ HER2- breast cancer
  • capivasertib + abiraterone CAPItello-281 PTEN缺乏转移性激素敏感性前列腺癌
  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + docetaxel CAPItello-280 mCRPC prostate cancer
  • capivasertib + fulvestrant + palbociclib CAPItello-292 一线三胞胎早期复发/ET耐药局部晚期(不能手术)或转移性乳腺癌
  • capivasertib + fulvestrant CAPItello-291 二线及以上的抗AI局部晚期(不能手术)或转移性乳腺癌
  • ceralasertib + Imfinzi LATIFY non-small cell lung cancer
  • ceralasertib + Imfinzi MONETTE melanoma
  • datopotamab deructucan AVANZAR 1L NSCLC,鳞状和非鳞状1L NSCLC, TROP2 BM+
  • datopotamab deruxtecan TROPION Lung07 1L NSCLC PD-L1 <50% non-squamous
  • datopotamab deruxtecan TROPION Lung08 没有可操作的基因组改变的1L转移性NSCLC, PD-L1 TPS≥50%
  • datopotamab deruxtecan TROPION-Breast01 2-3L HR+ HER2- breast cancer
  • datopotamab deruxtecan TROPION-Breast02 1st-line triple negative breast cancer
  • datopotamab deruxtecan TROPION-Breast03 三阴性乳腺癌
  • datopotamab deruxtecan TROPION-Lung01 2L+ NSCLC伴或不伴可操作的基因组改变
  • Imfinzi + Imjudo HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi +- oleclumab +- monalizumab PACIFIC-9 unresectable stage III NSCLC

LCM Projects

LCM Projects

  • Calquence + R-CHOP ESCALADE 1st-line diffuse large B cell lymphoma
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Enhertu (platform) DESTINY-Breast07 HER2+ breast cancer
  • Enhertu (platform) DESTINY-Breast08 HER2-low breast cancer
  • Enhertu DESTINY-Breast02 HER2+, 不可切除和/或转移性乳腺癌之前的护理标准HER2治疗, including T-DM1
  • Enhertu DESTINY-Breast03 HER2+, 既往接受曲妥珠单抗和紫杉烷治疗的不可切除和/或转移性乳腺癌患者
  • Enhertu DESTINY-Breast04 her2低、不可切除和/或转移性乳腺癌患者
  • Enhertu DESTINY-Breast05 HER2+ post-neoadjuvant high-risk breast cancer
  • Enhertu DESTINY-Breast06 post-ET HER2-low/HR+ breast cancer 2L
  • Enhertu DESTINY-Breast09 1st-line HER2+ breast cancer
  • Enhertu DESTINY-Breast11 Neoadjuvant HER2+ breast cancer
  • Enhertu DESTINY-Gastric01 her2过表达的晚期胃或胃食管交界处腺癌患者,既往两种治疗方案均有进展
  • Enhertu DESTINY-Gastric04 2nd-line HER2+ gastric cancer
  • Enhertu DESTINY-Lung01 her2过表达或突变,不可切除和/或转移性非小细胞肺癌
  • Enhertu DESTINY-Lung04 1st-line HER2m non-small cell lung cancer
  • Enhertu DESTINY-PanTumour01 HER2 mutant tumours
  • Enhertu DESTINY-PanTumour02 HER2 expressing solid tumours
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) COAST non-small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + CRT KUNLUN 局部晚期食管鳞状细胞癌
  • Imfinzi + CRT PACIFIC-2 局部晚期(III期)非小细胞肺癌
  • Imfinzi + CRT PACIFIC-5 (China) 局部晚期(III期)非小细胞肺癌
  • Imfinzi + CTx neoadjuvant AEGEAN 局部晚期(II-III期)非小细胞肺癌
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + domvanalimab (AB154) PACIFIC-8 unresectable stage III non-small cell lung cancer
  • Imfinzi + EV +/- Imjudo VOLGA muscle invasive bladder cancer
  • Imfinzi + FLOT MATTERHORN neo-adjuvant/adjuvant gastric cancer
  • Imfinzi + Imjudo + SoC NILE 1st-line urothelial cancer
  • Imfinzi + Imjudo + TACE +/- lenvatinib EMERALD-3 locoregional hepatocellular carcinoma
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi +/- Imjudo + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- Imjudo + CTx POSEIDON 1st-line non-small cell lung cancer
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Imfinzi POTOMAC non-muscle invasive bladder cancer
  • Lynparza (basket) LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • Lynparza + Imfinzi DUO-E 1st-line endometrial cancer
  • Lynparza MONO-OLA1 1st-line BRCAwt ovarian cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Orpathys + Imfinzi SAMETA 1st-line papillary renal cell carcinoma
  • Tagrisso + (Koselugo or Orpathys) TATTON advanced EGFRm non-small cell lung cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso + Orpathys SAFFRON advanced EGFRm non-small cell lung cancer
  • Tagrisso + Orpathys SAVANNAH advanced EGFRm non-small cell lung cancer
  • Tagrisso +/- CTx neoadjuvant NeoADAURA stage II/III resectable EGFRm NSCLC
  • Tagrisso ADAURA2 肿瘤完全切除后的辅助EGFRm NSCLC分期Ia2-Ia3
  • Tagrisso LAURA stage III EGFRm non-small cell lung cancer
  • Tagrisso ORCHARD platform study 2nd-line EGFRm osimertinib-resistant NSCLC

心血管、肾脏及新陈代谢(截至2023年2月9日)

Phase I

Phase I

  • AZD0186 type-2 diabetes
  • AZD0780 dyslipidaemia
  • AZD2373 nephropathy
  • AZD2693 non-alcoholic steatohepatitis
  • AZD3366 cardiovascular disease
  • AZD3427 cardiovascular disease
  • AZD5462 cardiovascular disease
  • AZD6234 obesity with related comorbidities
  • AZD7503 non-alcoholic steatohepatitis

Phase II

Phase II

  • balcinrenone/dapagliflozin heart failure with CKD
  • cotadutide non-alcoholic steatohepatitis
  • MEDI6570 cardiovascular disease
  • mitiperstat 心脏衰竭,射血分数保留/ NASH
  • tozorakimab diabetic kidney disease
  • zibotentan/dapagliflozin chronic kidney disease

Phase III

Phase III

  • Andexxa Acute Major Bleed
  • eplontersen 遗传性或野生型转甲状腺素介导的淀粉样心肌病(ATTR CM)患者
  • eplontersen 遗传性转甲状腺素介导的淀粉样多神经病变(hat - pn)患者
  • roxadustat OLYMPUS ROCKIES 慢性肾病/终末期肾病中的贫血

LCM Projects

LCM Projects

  • Andexxa urgent surgery
  • Farxiga/Forxiga DAPA-MI 心肌梗死后心力衰竭和CV死亡的预防
  • Farxiga/Forxiga DELIVER 慢性心力衰竭患者心衰或CV死亡加重(HFpEF)
  • Lokelma DIALIZE-Outcomes 伴有高钾血症的慢性血液透析患者的CV结局
  • Lokelma STABILIZE-CKD hyperkalaemia in CKD
  • roxadustat chemotherapy induced anaemia
  • roxadustat anaemia in myelodysplastic syndrome
  • Xigduo XR/Xigduo type-2 diabetes

Respiratory & Immunology (as of 9 February 2023)

Phase I

Phase I

  • AZD4604 asthma
  • AZD5055 idiopathic pulmonary fibrosis
  • AZD6793 inflammatory diseases
  • AZD7798 Crohn's disease
  • AZD8630 asthma

Phase II

Phase II

  • atuliflapon Asthma
  • brazikumab EXPEDITION ulcerative colitis
  • elarekibep (AZD1402) asthma
  • mitiperstat COPD
  • tozorakimab FRONTIER 3 Asthma

Phase III

Phase III

  • Airsupra (PT027) asthma
  • brazikumab INTREPID Crohn's disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • Saphnelo TULIP 1 & TULIP 2 AZALEA (China) systemic lupus erythematosus
  • Tezspire NAVIGATOR DIRECTION severe uncontrolled asthma
  • tozorakimab OBERON TITANIA chronic obstructive pulmonary disease
  • tozorakimab TILIA acute respiratory failure

LCM Projects

LCM Projects

  • Breztri/Trixeo (PT010) KALOS LOGOS asthma
  • Fasenra FJORD bullous pemphigoid
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra ORCHID nasal polyps
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Saphnelo IRIS lupus nephritis
  • Saphnelo TULIP-SC systemic lupus erythematosus (subcutaneous)
  • Tezspire COURSE chronic obstructive pulmonary disease
  • Tezspire WAYPOINT nasal polyps

Rare Disease (as of 9 February 2023)

Phase I

Phase I

  • ALXN1820 haematology
  • ALXN1850 hypophosphatasia
  • ALXN1910 bone metabolism
  • ALXN2030 nephrology
  • ALXN2080 healthy volunteers
  • NI006 transthyretin amyloid cardiomyopathy

Phase II

Phase II

  • danicopan geographic atrophy
  • vemircopan paroxysmal nocturnal haemoglobinuria
  • vemircopan generalized myasthenia gravis
  • vemircopan 增生性狼疮肾炎或免疫球蛋白A肾病

Phase III

Phase III

  • acoramidis transthyretin amyloid cardiomyopathy
  • ALXN1840 Wilsons disease
  • anselamimab (CAEL-101) AL amyloidosis
  • danicopan 阵发性夜间血红蛋白尿伴血管外溶血
  • gefurulimab generalised myasthenia gravis
  • Koselugo/selumetinib SPRINT paediatric neurofibromatosis type-1

LCM Projects

LCM Projects

  • Ultomiris dermatomyositis
  • Ultomiris 造血干细胞移植相关的血栓性微血管病
  • Ultomiris generalised myasthenia gravis
  • Ultomiris 皮下,阵发性夜间血红蛋白尿和非典型溶血性尿毒综合征
  • Ultomiris CHAMPION-NMOSD neuromyelitis optica spectrum disorder

Vaccine & Immune therapies (as of 9 February 2023)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

  • AZD3152 SUPERNOVA prevention of COVID-19
  • Beyfortus passive RSV immunisation
  • Evusheld prevention and treatment of COVID-19

LCM Projects

LCM Projects

Other (as of 9 February 2023)

Phase I

Phase I

  • AZD4041 Opioid use disorder
  • MEDI0618 osteoarthritis pain
  • MEDI1814 alzheimer’s disease

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Removed since last quarter